[
  {
    "ts": null,
    "headline": "Stocks Churn as Busy Earnings Week to Test Rally: Markets Wrap",
    "summary": "(Bloomberg) -- Wall Street traders bracing for a deluge of corporate earnings and key economic data sent stocks churning on Monday as they awaited more insights on the impacts of President Donald Trump’s trade war.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryLos Angeles Downgraded to AA- by S&P Due to Budget WoesUS Cricket Deepens Bet on Texas With HQ Shift From CaliforniaThe Last Thing U",
    "url": "https://finnhub.io/api/news?id=068217683677097bf96c79dd9b3261221bf57f20be61457d35169a1cde3284dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745852029,
      "headline": "Stocks Churn as Busy Earnings Week to Test Rally: Markets Wrap",
      "id": 134114876,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Wall Street traders bracing for a deluge of corporate earnings and key economic data sent stocks churning on Monday as they awaited more insights on the impacts of President Donald Trump’s trade war.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryLos Angeles Downgraded to AA- by S&P Due to Budget WoesUS Cricket Deepens Bet on Texas With HQ Shift From CaliforniaThe Last Thing U",
      "url": "https://finnhub.io/api/news?id=068217683677097bf96c79dd9b3261221bf57f20be61457d35169a1cde3284dd"
    }
  },
  {
    "ts": null,
    "headline": "Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline",
    "summary": "Zymeworks receives Strong Buy rating, driven by FDA-approved Ziihera, advancing R&D, strong partnerships, and financial health.",
    "url": "https://finnhub.io/api/news?id=a4bccbebae64b2288cd7ad17e1db731193cbf06cd0ff56fd86ad9036211ba03b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745861583,
      "headline": "Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline",
      "id": 134119553,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160714898/image_2160714898.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Zymeworks receives Strong Buy rating, driven by FDA-approved Ziihera, advancing R&D, strong partnerships, and financial health.",
      "url": "https://finnhub.io/api/news?id=a4bccbebae64b2288cd7ad17e1db731193cbf06cd0ff56fd86ad9036211ba03b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: Why Orforglipron Matters, A Lot",
    "summary": "Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral obesity drug. Click for my LLY update.",
    "url": "https://finnhub.io/api/news?id=7318416a401515a3ba029aeb5873035beacd58e657832ccd46193eeed2e5e3bc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745856808,
      "headline": "Eli Lilly: Why Orforglipron Matters, A Lot",
      "id": 134118833,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156400243/image_2156400243.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral obesity drug. Click for my LLY update.",
      "url": "https://finnhub.io/api/news?id=7318416a401515a3ba029aeb5873035beacd58e657832ccd46193eeed2e5e3bc"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?",
    "summary": "Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.",
    "url": "https://finnhub.io/api/news?id=0baf42e6b97681e5c18609832f6de6672ad5abe20f1451bccc8d6c2b17fbbd65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745856480,
      "headline": "Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?",
      "id": 134130904,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.",
      "url": "https://finnhub.io/api/news?id=0baf42e6b97681e5c18609832f6de6672ad5abe20f1451bccc8d6c2b17fbbd65"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)",
    "summary": "Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.",
    "url": "https://finnhub.io/api/news?id=f05c5d8f47879ea9825021b33b69461d09181704e4eb7182b07ce3d02319575c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745854860,
      "headline": "Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)",
      "id": 134130905,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.",
      "url": "https://finnhub.io/api/news?id=f05c5d8f47879ea9825021b33b69461d09181704e4eb7182b07ce3d02319575c"
    }
  },
  {
    "ts": null,
    "headline": "HSBC cuts biotech stocks: Eli Lilly lowered to Reduce",
    "summary": "Investing.com -- HSBC downgraded several major biotech names this week, citing macroeconomic sensitivities, tariff risks, and growing pressure from regulatory changes. Most notably, the bank downgraded Lilly to Reduce from Buy.",
    "url": "https://finnhub.io/api/news?id=0a27d1dc896282ce0f6e66006e9d97a3af82e436b644de5b34131b80fdff762c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745854673,
      "headline": "HSBC cuts biotech stocks: Eli Lilly lowered to Reduce",
      "id": 134130906,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- HSBC downgraded several major biotech names this week, citing macroeconomic sensitivities, tariff risks, and growing pressure from regulatory changes. Most notably, the bank downgraded Lilly to Reduce from Buy.",
      "url": "https://finnhub.io/api/news?id=0a27d1dc896282ce0f6e66006e9d97a3af82e436b644de5b34131b80fdff762c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Pfizer Risk Billions in Losses From Trump's 25% Pharma Tariffs",
    "summary": "Trump's Pharma Tariff Plan Could Cost Eli Lilly, Pfizer, Amgen $51B a Year",
    "url": "https://finnhub.io/api/news?id=58fa783b95fdbb9abba48ed042be0996576e0fead0d7d94b3f2706f98374e7e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745853637,
      "headline": "Eli Lilly, Pfizer Risk Billions in Losses From Trump's 25% Pharma Tariffs",
      "id": 134115299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trump's Pharma Tariff Plan Could Cost Eli Lilly, Pfizer, Amgen $51B a Year",
      "url": "https://finnhub.io/api/news?id=58fa783b95fdbb9abba48ed042be0996576e0fead0d7d94b3f2706f98374e7e8"
    }
  },
  {
    "ts": null,
    "headline": "Boeing, Jack in the Box, Eli Lilly: Trending Tickers",
    "summary": "Brad Smith and Madison Mills take a closer look at some of today's trending tickers and top calls from Wall Street analysts on Morning Brief. Boeing (BA) is in focus after Bernstein analysts upgraded the stock to Outperform from Market Perform. Jack in the Box (JACK) also saw a rating upgrade from Stifel analysts, who upgraded the company's stock to Buy from Hold. Eli Lilly (LLY), on the other hand, saw a double downgrade from HSBC analysts. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=eae2a324ac2d27d2017cbbeb863566777439a9cec76f5a9262ddb853d09408f6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745849596,
      "headline": "Boeing, Jack in the Box, Eli Lilly: Trending Tickers",
      "id": 134115031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Brad Smith and Madison Mills take a closer look at some of today's trending tickers and top calls from Wall Street analysts on Morning Brief. Boeing (BA) is in focus after Bernstein analysts upgraded the stock to Outperform from Market Perform. Jack in the Box (JACK) also saw a rating upgrade from Stifel analysts, who upgraded the company's stock to Buy from Hold. Eli Lilly (LLY), on the other hand, saw a double downgrade from HSBC analysts. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=eae2a324ac2d27d2017cbbeb863566777439a9cec76f5a9262ddb853d09408f6"
    }
  },
  {
    "ts": null,
    "headline": "Ahead of Lilly (LLY) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
    "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.",
    "url": "https://finnhub.io/api/news?id=5d0c71d3f658b3c1fec77e5975cd9b2757749dccb4d3bebbf71499a83f2917c9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745846164,
      "headline": "Ahead of Lilly (LLY) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
      "id": 134115032,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.",
      "url": "https://finnhub.io/api/news?id=5d0c71d3f658b3c1fec77e5975cd9b2757749dccb4d3bebbf71499a83f2917c9"
    }
  },
  {
    "ts": null,
    "headline": "HSBC Downgrades Eli Lilly and (LLY)",
    "summary": "HSBC Downgrades Eli Lilly and (LLY)",
    "url": "https://finnhub.io/api/news?id=415236e26eddcb35b53b4006a74421dac9dc809d3865277e342c3e349edc858d",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745841770,
      "headline": "HSBC Downgrades Eli Lilly and (LLY)",
      "id": 134113690,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=415236e26eddcb35b53b4006a74421dac9dc809d3865277e342c3e349edc858d"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?",
    "summary": "Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.",
    "url": "https://finnhub.io/api/news?id=1425b5b9d7f81e0da9a4e33f397c5568a136d4eed3489eb3657ac9f6bdc2f579",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745840700,
      "headline": "Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?",
      "id": 134115033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.",
      "url": "https://finnhub.io/api/news?id=1425b5b9d7f81e0da9a4e33f397c5568a136d4eed3489eb3657ac9f6bdc2f579"
    }
  },
  {
    "ts": null,
    "headline": "Tariff War Draws Investment Warning From $160 Billion Novo Fund",
    "summary": "(Bloomberg) -- The $160 billion fund behind Ozempic-maker Novo Nordisk A/S says President Donald Trump’s tariff war has created so much economic uncertainty that it now sees little likelihood it will move ahead with any big investments.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryLos Angeles Downgraded to AA- by S&P Due to Budget WoesUS Cricket Deepens Bet on Texas With HQ Shift From Cali",
    "url": "https://finnhub.io/api/news?id=4db367806fc200a570600b19fcd212c3e2ec62d8945567962a428ee0a4e966aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745838435,
      "headline": "Tariff War Draws Investment Warning From $160 Billion Novo Fund",
      "id": 134115034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- The $160 billion fund behind Ozempic-maker Novo Nordisk A/S says President Donald Trump’s tariff war has created so much economic uncertainty that it now sees little likelihood it will move ahead with any big investments.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryLos Angeles Downgraded to AA- by S&P Due to Budget WoesUS Cricket Deepens Bet on Texas With HQ Shift From Cali",
      "url": "https://finnhub.io/api/news?id=4db367806fc200a570600b19fcd212c3e2ec62d8945567962a428ee0a4e966aa"
    }
  }
]